Effektivnost' lecheniya tyazhelogo predmenstrual'nogo sindroma drospirenonsoderzhashchim preparatom


Cite item

Full Text

Abstract

About the authors

A V Ledina

V N Prilepskaya

References

  1. Аганезова Н.В. Ассоциация функциональных вариантов генов транспортеров серотонина и дофамина с психовегетативными нарушениями у больных с предменструальным синдромом. VII Всероссийская научно-практическая конференция с международным участием «Молекулярная диагностика - 2010». Сб. тр. Под ред. В.И.Покровского. 2010. Т. 3 (разд. 13): 4, 5.
  2. Прилепская В.Н., Межевитинова Е.А. Предменструальный синдром. Гинекология. 2005; 7 (4): 210-4.
  3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press, 1994.
  4. Andréen L et al. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 2009; 34 (8): 1121-32.
  5. Finocchi C, Ferrari M. Female reproductive steroids and neuronal excitability. Neurol Sci 2011; 32: S31-5.
  6. Freeman EW, Sondheimer SJ. Premenstrual dysphoric disorder: recognition and treatment. Primary Care Companion. J Clin Psychiatry 2003; 5: 30-9.
  7. Halbreich U et al. Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand 1986; 74 (6): 576-86.
  8. Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol 1994; 170 (5 Pt 2): 1499-507.
  9. Machado RB et al. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond Engl) 2011; 7 (1): 19-30.
  10. Marr J et al. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet 2011; 113 (2): 103-7.
  11. Mishell DR. YAZ and the novel progestin drospirenone. J Reprod Med 2008; 53 (Suppl. 9): 721-8.
  12. O'Brien PM et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health 2011; 14 (1): 13-21.
  13. OelkersW. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004; 217 (1-2): 255-61.
  14. Oinonen K, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J Affect Disord 2002; 70 (3): 229-40.
  15. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61 (2): 105-11.
  16. Pearlstein TB et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation Contraception 2005; 72 (6): 414-21.
  17. Pinkerton JV. The menstrual cycle-mood disorder tandem: Screening, diagnosis, and treatment. OBG Management 2011; 23 (12): 24-9.
  18. Rapkin AJ et al. Oral contraceptives and neuroactive steroids. Pharmacol Biochem Behav 2006; 84 (4): 628-34.
  19. Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception 2005; 71 (1): 1-7.
  20. Steiner M, Born L. Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 2000; 15 (Suppl. 3): S5-17.
  21. Usman SB et al. Hormonal management of premenstrual syndrome. Best Pract Res Clin Obstet Gynaecol 2008; 22 (2): 251-60.
  22. Yonkers KA et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106 (3): 492-501.

Copyright (c) 2012 Ledina A.V., Prilepskaya V.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies